Moleculin Biotech Annamycin Doublet Therapy Shows 68% Overall Survival In Animal Study

 Moleculin Biotech Inc 

MBRX -2.7%

 (Get Free Alerts for MBRX) has announced preliminary results supporting the successful conclusion of its second Phase 1 trial in Poland, evaluating Annamycin for relapsed and refractory acute myeloid leukemia (AML).

• Moleculin determined a dose of 240 mg/m2 as the Recommended Phase 2 Dose (RP2D), subject to final approval of the Safety Review Committee, and indicated no signs of cardiotoxicity. 
• Based on preclinical animal data, Annamycin in combination with Cytarabine demonstrated a 68% improvement in the median overall survival (OS) compared to Annamycin as a single agent and a 241% increase in OS compared to Cytarabine alone. 
• The Company plans to advance its AML clinical development program in a Phase 1/2 clinical trial in Europe, evaluating Annamycin/Cytarabine combo.
• The study is expected to begin in 1H 2022.
• Annamycin has demonstrated no cardiotoxicity to date, with an ORR of 60% in the last cohort for patients receiving a full course of Annamycin.

https://www.benzinga.com/general/biotech/22/02/25607167/moleculin-biotech-annamycin-doublet-therapy-shows-68-overall-survival-in-animal-study